Biomerica Announces inFoods® IBS Pilot Launch with Prominent 1,100 Member Physician Group Commencing June 2024
13 mai 2024 08h19 HE
|
Biomerica, Inc.
With IBS affecting 10 to 15% of the global population, the associated $21 billion in direct medical costs and absenteeism underscores the urgent need of innovative solutions. Recognized as the 7th...
Biomerica provides update on inFoods® IBS expansion
15 avr. 2024 07h47 HE
|
Biomerica, Inc.
- Expansion into new offices within current major groups, including Northeast and Ohio; Expansion into new major group in Texas. - Average quarterly increase in physicians prescribing inFoods more...
Biomerica InFoods IBS Data to be Presented at the Upcoming Digestive Disease Week (DDW) 2024 Conference
28 mars 2024 08h19 HE
|
Biomerica, Inc.
Collaborators at the University of Michigan will present new Data on InFoods® IBS in the DDW Irritable Bowel Syndrome (IBS) Clinical Session IRVINE, Calif., March 28, 2024 (GLOBE NEWSWIRE) --...
Biomerica Reports Second Quarter 2024 Financial Results
16 janv. 2024 08h19 HE
|
Biomerica, Inc.
Revenues excluding Covid test sales increased 10.3% for the second fiscal quarter of 2024 vs the second fiscal quarter of 2023.Loss per shares narrows to $0.09 per share from $0.12 per share...
Biomerica Expands inFoods IBS Reach with Addition of Several New GI Groups
08 nov. 2023 08h19 HE
|
Biomerica, Inc.
Biomerica remains on track for inFoods® IBS national rollout during calendar 2024, and expects strong product revenue growth during national rolloutVeteran Vice President of Sales and National...
Diagnostics Industry Leader Jack Kenny Joins Biomerica’s Board of Directors
28 août 2023 08h19 HE
|
Biomerica, Inc.
Kenny has proven track record of driving growth at companies within the healthcare space and holds significant management and public company board experience, most recently as CEO of Meridian...
Biomerica Reports Fiscal 2023 Year End Results
25 août 2023 17h00 HE
|
Biomerica, Inc.
Revenues excluding Covid test sales increased 15% for fiscal 2023 vs fiscal 2022 Successfully completed inFoods® IBS pilot program with one of the largest Gastrointestinal physician groups in the US ...
Biomerica’s inFoods® IBS test is now available at Gastro Health, providing a revolutionary new treatment for patients suffering from Irritable Bowel Syndrome (IBS).
17 avr. 2023 07h47 HE
|
Biomerica, Inc.
Gastro Health is a leading gastroenterology group with over 380 GI physicians in the United StatesClinical study results show patients who eliminated foods as determined by the inFoods® IBS test...
Biomerica announces the Launch of InFoods IBS as a Laboratory Developed Test (LDT); First patient samples have been processed
08 mars 2023 08h19 HE
|
Biomerica, Inc.
InFoods® IBS LDT validation testing at the CLIA Lab is completed and the product is now being offered commerciallyClinical trial data shows InFoods® IBS treatment diet significantly improved several...
Biomerica Appoints Mayo Clinic Gastroenterologist, Dr. Brian E. Lacy, to the Company’s Scientific Advisory Board
10 janv. 2023 08h19 HE
|
Biomerica, Inc.
Dr. Lacy is the former co-Editor in Chief of the American Journal of Gastroenterology, the former Editor in Chief of Clinical and Translational Gastroenterology, and has served as the co-Chairman for...